CathVision

Highlights ⭐

• Solving the problem: Traditional EP recording systems are expensive, limited in capability and deliver substandard electrogram signals, creating an unacceptable status quo that reduces the ability to effectively diagnose and determine therapy for complex cardiac arrhythmia.
• Already in use: Since receiving FDA clearance in May of 2022, several world-renowned hospitals have repeatedly utilized the ECGenius System during the current limited market release. These include Cleveland Clinic, Johns Hopkins Hospital, Houston Methodist Hospital, IU Health Methodist Hospital, NYU Langone Health, and Valley Health. Leading electrophysiologists at these hospitals have recognized ECGenius' ability to provide clear signal data that helps clinicians identify, diagnose, and treat complex cardiac arrhythmias. As a result, in many EP labs, the ECGenius System has replaced existing EP recording systems, including LabSystem Pro and CardioLab, as the primary EP system for measuring, analyzing, recording, and routing pacing. 🔗
• Patented tech: CathVision's core IP is centered on both low-noise inventions (ECGenius System) and algorithm innovation (CARDIALYTICS). The company's technologies are covered by 13 patent families, of which six are granted, and seven are pending. 🔗
• Scientific recognition: CathVision's ECGenius System and CARDIALYTICS' AI-based analytics have received industry recognition, with seven scientific abstracts featuring the technology accepted for presentation at the Heart Rhythm Society (HRS) conference in New Orleans. This attention further solidifies ECGenius System's place as an exciting technology that will advance the field of electrophysiology. 🔗